clinical trial · NCT07633470
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Alpha Cognition, Inc·phase4·recruiting·n = 150
Alzheimer DiseaseZunveyl®
brief summary
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
started
May 20, 2026
primary completion
Apr 1, 2027
completion
Apr 1, 2027
last updated
Jul 20, 2026
official title
RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol